Old Web
English
Sign In
Acemap
>
authorDetail
>
Nirav Bhalani
Nirav Bhalani
Sama
open label study
Internal medicine
Pegylated interferon alfa-2b
Coronavirus disease 2019
2019 20 coronavirus outbreak
2
Papers
15
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Corrigendum to "Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study" [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521].
2021
International Journal of Infectious Diseases
Anuja Pandit
Nirav Bhalani
B.L. Shashi Bhushan
Parshottam Koradia
Shweta Gargiya
Vinay Bhomia
Kevinkumar Kansagra
Show All
Source
Cite
Save
Citations (0)
Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.
2021
International Journal of Infectious Diseases
Anuja Pandit
Nirav Bhalani
B.L. Shashi Bhushan
Parshottam Koradia
Shweta Gargiya
Vinay Bhomia
Kevinkumar Kansagra
Show All
Source
Cite
Save
Citations (15)
1